The Continuous Bioprocessing Market is projected to reach $1.32 billion by 2031 at a CAGR of 19.6% from 2024 to 2031. Continuous bioprocessing consists of integrated continuous unit processes without intermediate holding tanks through which product travels into containers in a constant flow. Continuous unit operations are characterized by extremely intensified processing with short downtimes. An end-to-end bioprocess involves a perfusion bioreactor, multi-column chromatography systems, and multi-column intermediate purification. Some pharmaceutical and biopharmaceutical manufacturers adopt a hybrid approach for continuous biopharmaceutical manufacturing in which only the upstream or downstream process is continuous.
read more..